Background/Aims: To determine the changes in body weight and bone mineral density in patients with ankylosing spondylitis (AS) receiving anti-tumor necrosis factor-α (TNF-α) treatment. Methods: Thirty-one patients with AS (25 males and 6 females) who fulfilled the Modified New York Criteria for AS were included in this retrospective study. All patients had active disease that eventually required anti-TNF-α treatment. Each patient received anti-TNF-α treatment (etanercept 25 mg twice weekly or adalimumab 40 mg twice monthly) for more than 2 years. Body weight, disease activity as Bath ankylosing spondylitis disease activity index (BASDAI), C-reactive protein, erythrocyte sedimentation rate (ESR), lumbar bone mineral density (LBMD), and femoral bone mineral density (FBMD) were measured at baseline and at 1 and 2 years after initiating anti-TNF-α treatment. Results: There was a significant increase in mean body weight at 1 year (1.1 ± 3.8 kg) and at 2 years (1.7 ± 4.8 kg) compared with baseline. The gains in mean BMD of the lumbar spine were significant at 1 year (0.4 ± 0.4) and 2 years (0.5 ± 0.7) compared with baseline. Mean BMD of the femur was also increased at 1 year (0.08 ± 0.7) and 2 years (0.1 ± 0.8) compared with baseline, but these differences were not statistically significant. There were significant decreases in BASDAI at 1 year (-3.3 ± 2.8) and at 2 years (-3.6 ± 2.8) compared with baseline. Conclusions: This study showed significant increases in body weight, lumbar BMD, and BASDAI at 1 year and 2 years in patients with ankylosing spondylitis after receiving anti-TNF-α treatment. (Korean J Med 2013;85:489-494) 
AS, ankylosing spondylitis; BASDAI, Bath ankylosing spondylitis disease activity index; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; n, number; BMI, body mass index. Table 2) . 
